Last updated: October 5, 2026
Istodax, the brand name for romidepsin, is a histone deacetylase inhibitor developed for relapsed or refractory cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Its commercial trajectory has been limited by a small addressable market, intravenous administration, competition from newer targeted therapies, and the failure of combination-development programs. Bristol Myers Squibb has not disclosed standalone Istodax revenue in recent public filings, and the product has had little strategic visibility following the Celgene acquisition.
What is Istodax and which cancer indications does it treat?
Istodax is an intravenous formulation of romidepsin, a class I histone deacetylase inhibitor. The FDA approved it under the accelerated-approval pathway for relapsed or refractory CTCL and later for relapsed or refractory PTCL after at least one prior systemic therapy.[1,2]
| Attribute |
Istodax profile |
| Active ingredient |
Romidepsin |
| Brand |
Istodax |
| Drug class |
Histone deacetylase inhibitor |
| Route |
Intravenous infusion |
| Original sponsor |
Celgene |
| Current corporate owner |
Bristol Myers Squibb, following Celgene acquisition |
| First FDA approval |
November 2009 |
| CTCL use |
Relapsed or refractory disease |
| PTCL use |
Relapsed or refractory disease after at least one prior therapy |
| FDA pathway |
Accelerated approval |
| Orphan-drug status |
Yes |
| Biosimilar exposure |
None; romidepsin is a small molecule |
Romidepsin was one of the earliest systemic therapies with meaningful activity in relapsed CTCL and PTCL. Its commercial role has remained concentrated in later-line treatment rather than frontline therapy.
How large is the Istodax market?
The Istodax market is constrained by disease prevalence, later-line positioning, and intravenous delivery.
CTCL and PTCL are uncommon hematologic malignancies. The eligible population is smaller than the population for multiple myeloma, diffuse large B-cell lymphoma, or chronic lymphocytic leukemia. Patients also cycle through several therapies, reducing duration of treatment for any individual product.
The principal demand drivers have been:
- Relapsed or refractory disease.
- Patients requiring systemic treatment.
- Use after prior chemotherapy or targeted therapy.
- Treatment at specialist cancer centers.
- Physician familiarity with the drug’s safety and response profile.
The principal market constraints have been:
- Low patient volume.
- Infusion-center administration.
- Frequent adverse events, including nausea, fatigue, cytopenias, infection risk, and electrocardiographic concerns.
- Competition from oral and targeted agents.
- Limited differentiation in an increasingly crowded lymphoma market.
- Lack of a successful combination program that could have moved romidepsin into earlier treatment lines.
Romidepsin’s market was never comparable with Celgene’s major products such as Revlimid or Pomalyst. The product was strategically relevant as part of Celgene’s hematology-oncology portfolio but was not a material driver of consolidated revenue.
What is the financial trajectory of Istodax?
Bristol Myers Squibb does not generally report Istodax as a separate revenue line. Public filings aggregate products into broader categories, and the company has not provided a recurring, transparent product-level revenue series for romidepsin.[3]
Revenue trajectory
The commercial pattern is best characterized as a modest specialty-oncology product followed by declining strategic importance.
| Period |
Commercial position |
Financial interpretation |
| 2009-2011 |
Initial CTCL approval and PTCL expansion |
Market entry with orphan-drug pricing and specialist adoption |
| 2012-2017 |
Established later-line hematology product |
Stable but limited demand, constrained by rare-disease volume |
| 2018-2019 |
Celgene portfolio maturity |
Revenue remained small relative to Revlimid, Pomalyst and Abraxane |
| 2019-2021 |
BMS integration after Celgene acquisition |
Product-level reporting became less visible |
| 2021 onward |
Development retrenchment and weak commercial momentum |
Reduced probability of meaningful growth or label expansion |
No public evidence indicates that Istodax generated blockbuster-level sales. Its economic value came from incremental oncology revenue, portfolio breadth, and clinical optionality rather than scale.
Why did revenue growth remain limited?
Romidepsin’s commercial ceiling was shaped by the treatment setting. Relapsed CTCL and PTCL patients often receive multiple therapies, while the total number of treated patients is small. Intravenous treatment also increases administration costs and limits convenience relative to oral agents.
The product’s efficacy was sufficient for regulatory approval, but its clinical profile did not create a broad therapeutic franchise. The drug lacked a large first-line indication and did not secure a major role in combination regimens.
What FDA milestones shaped Istodax’s commercial value?
Istodax received FDA approval for CTCL in 2009 based on response data in patients with relapsed or refractory disease.[1] The FDA later approved the drug for PTCL in 2011 after at least one prior systemic therapy.[2]
The PTCL approval carried the commercial potential to expand use beyond CTCL, but the indication remained limited to a small and heavily pretreated population. Accelerated approval also created an obligation to support additional clinical evidence.
A major setback occurred when the phase 3 ROMIplus study evaluating romidepsin with CHOP chemotherapy in previously untreated PTCL failed to improve progression-free survival or overall survival sufficiently to support a frontline strategy.[4] The failure reduced the likelihood that romidepsin would move into a larger, earlier-line market.
Bristol Myers Squibb also discontinued development of romidepsin in combination with azacitidine after the program failed to produce the expected clinical benefit in a randomized study.[5] This removed another potential expansion path.
When does Istodax lose exclusivity?
The key commercial exclusivity periods for Istodax have largely expired.
Regulatory exclusivity
The original CTCL and PTCL approvals received orphan-drug exclusivity. Orphan exclusivity generally lasts seven years from approval in the United States, subject to statutory conditions. The CTCL exclusivity period therefore ended years ago, and the PTCL exclusivity period also expired after its 2011 approval.
Istodax is not protected by biologic exclusivity because romidepsin is a small molecule. It also does not have the 12-year reference-product exclusivity associated with biologics.
Patent protection
Romidepsin’s principal composition-of-matter protection was filed long before the FDA approvals. The practical term for the earliest core patent family reached the end of its ordinary U.S. life around the early 2020s, subject to patent-term adjustment, patent-term extension, and claim-specific analysis.
The commercial protection profile is therefore materially weaker than that of recently launched oncology products with unexpired composition, formulation, and method-of-use patents. Any remaining enforceable claims would need to be evaluated by patent family, jurisdiction, approved use, and Orange Book listing status.
| Protection category |
Istodax position |
| Orphan exclusivity |
Expired |
| Small-molecule regulatory exclusivity |
Expired |
| Biologic exclusivity |
Not applicable |
| Core composition patent |
Likely expired or at the end of term, depending on claim and jurisdiction |
| Formulation patents |
No widely recognized, commercially decisive formulation barrier |
| Method-of-use patents |
Potentially relevant only if unexpired and listed for a specific approved indication |
| Pediatric exclusivity |
No material public indication of a current six-month extension |
| Patent litigation barrier |
No prominent, publicly reported current litigation comparable with major oncology products |
What patents protect Istodax and romidepsin?
The original intellectual-property position centered on romidepsin and related depsipeptide compounds rather than a highly differentiated delivery platform. The drug is also known as FK228 and is derived from a natural-product program associated with Fujisawa, later Astellas.
Patent protection historically covered:
- Romidepsin and related compounds.
- Pharmaceutical compositions containing the active ingredient.
- Antineoplastic uses.
- Processes associated with production or purification.
The most important commercial patent was the core compound protection. Once that protection expired or became commercially ineffective, the remaining estate offered limited ability to preserve branded pricing.
Are formulation patents a significant barrier?
Formulation protection is not widely regarded as the primary barrier for romidepsin. Istodax is administered as a conventional intravenous product rather than through a complex long-acting depot, implant, device, or proprietary delivery system.
A generic entrant would still face sterile manufacturing, analytical characterization, supply reliability, and oncology-center adoption hurdles. Those barriers are commercial and technical rather than equivalent to a strong, long-duration patent moat.
Are method-of-use patents important?
Method-of-use patents could theoretically protect a defined patient population, dosing schedule, combination, or treatment sequence. Their practical value would depend on:
- Whether the patent remains unexpired.
- Whether the claims cover an FDA-approved use.
- Whether the patent is listed in the Orange Book.
- Whether a generic applicant seeks approval for the protected indication.
- Whether a carve-out would allow a non-infringing label.
No publicly prominent current method-of-use estate has transformed Istodax into a high-barrier product.
What is the Orange Book status of Istodax?
Istodax was approved under NDA 022393. The FDA Orange Book historically provided the relevant reference-product and patent-listing information for the product.[6]
The commercial significance of any current Orange Book listing is limited by the age of the product and the absence of a widely reported active patent dispute. Patent listing status can change through delisting, expiration, correction, or regulatory updates. A patent’s appearance in the Orange Book would not by itself establish that a generic launch is blocked.
No major public Paragraph IV litigation campaign against Istodax is widely associated with the product. That differs from high-revenue oncology products where several generic or authorized-generic challengers may file before patent expiry.
Which companies compete with Istodax?
Istodax competes in two overlapping markets: the CTCL market and the PTCL market.
CTCL competitors
Relevant alternatives include:
- Vorinostat, marketed as Zolinza.
- Mogamulizumab, marketed as Poteligeo.
- Brentuximab vedotin, marketed as Adcetris, for eligible CD30-positive disease.
- Pralatrexate, marketed as Folotyn, in selected T-cell lymphoma settings.
- Extracorporeal photopheresis.
- Radiation, chemotherapy, and other systemic therapies.
Mogamulizumab has a targeted mechanism against CCR4 and is administered intravenously, while vorinostat offers oral administration. Brentuximab benefits from a defined CD30-positive population and has a broader commercial presence in hematologic oncology.
PTCL competitors
The competitive set includes:
- Belinostat, marketed as Beleodaq.
- Pralatrexate.
- Brentuximab vedotin for CD30-positive PTCL.
- Romidepsin.
- Conventional chemotherapy.
- Clinical-trial therapies, including antibody-drug conjugates, monoclonal antibodies, and cellular therapies.
PTCL treatment is increasingly segmented by biomarker status, prior treatment, transplant eligibility, and line of therapy. Romidepsin’s broad mechanism does not provide the same biomarker-driven differentiation as some newer agents.
Which companies challenged Istodax through Paragraph IV filings?
No major, widely reported Paragraph IV challenge has defined the current Istodax market. The absence of a prominent challenge does not mean generic competition is impossible. It reflects the product’s limited revenue opportunity, the technical requirements of sterile injectable manufacturing, and the relatively low incentive to fund expensive patent litigation against a small oncology market.
Potential generic entry would more likely arise after commercial discontinuation or patent exhaustion, depending on demand and manufacturing economics.
What generic launch risks exist for Istodax?
The probability of generic entry is higher than the probability of a major branded relaunch.
Generic-entry factors
| Factor |
Effect on generic risk |
| Core patent age |
Increases risk |
| Expired orphan exclusivity |
Increases risk |
| Intravenous sterile product |
Reduces immediate generic competition |
| Limited market size |
Reduces applicant incentive |
| Lack of complex delivery technology |
Increases technical feasibility |
| Oncology-center concentration |
Can slow substitution |
| Potential product discontinuation |
May reduce commercial attractiveness |
| Existing clinical alternatives |
Limits pricing power |
A generic version would need to meet FDA requirements for the relevant injectable dosage form, including quality, sterility, strength, purity, and manufacturing controls. For a small market, those requirements may be commercially difficult even when patent barriers are weak.
How strong is the Istodax patent estate?
The Istodax patent estate is weak by current specialty-pharmaceutical standards.
Its main strengths were historical:
- Early compound protection.
- Orphan-drug exclusivity.
- Established FDA approvals.
- Clinical data in two rare lymphoma indications.
Its current weaknesses are more important:
- Core protection is old.
- Regulatory exclusivity has expired.
- No biologic exclusivity applies.
- The product has limited formulation differentiation.
- The lead combination programs did not expand the label.
- The market is small and competitive.
- Patent litigation has not created a meaningful commercial barrier.
The estate may still contain jurisdiction-specific or claim-specific rights, but it does not appear to support a long-duration, high-value exclusivity thesis.
What licensing deals affected Istodax?
Celgene acquired rights and commercial responsibility for romidepsin through its corporate history, and Bristol Myers Squibb obtained the product through its acquisition of Celgene in 2019. The major economic event was therefore a corporate portfolio transfer rather than a new external licensing transaction that materially expanded romidepsin’s market.
Romidepsin’s original development history involved Japanese pharmaceutical research and natural-product licensing relationships, but those historical arrangements did not produce a durable late-life commercial expansion comparable with a partnered platform asset.
What litigation and settlement agreements affect Istodax?
No high-profile active patent litigation or settlement agreement is widely associated with Istodax as of the latest broadly available public information.
The absence of a settlement is commercially relevant. Branded oncology products often preserve market exclusivity through settlements with generic applicants. Istodax does not appear to have generated that level of generic challenge or litigation activity.
The more material legal issue is product and patent aging, not an active dispute over a long-lived patent estate.
What is the likely commercial outlook for Istodax?
Istodax has limited growth potential under its original commercial model.
Base-case outlook
The base case is a mature or declining specialty product with modest residual demand in relapsed lymphoma. Revenue remains small and is not separately disclosed by Bristol Myers Squibb.
Upside scenario
An upside scenario would require one or more of the following:
- A new biomarker-defined indication.
- A successful combination with an active targeted agent.
- A reformulated or more convenient dosage form.
- Reentry by another company into an underserved lymphoma niche.
- Evidence of meaningful activity in a genetically defined population.
The failed combination programs make this scenario less likely.
Downside scenario
The downside scenario is commercial discontinuation, restricted supply, or replacement by newer therapies and generic alternatives. A low-volume injectable product can become economically unattractive even before demand disappears.
How does Istodax compare with other HDAC inhibitors?
| Product |
Active ingredient |
Main use |
Route |
Commercial position |
| Istodax |
Romidepsin |
Relapsed CTCL and PTCL |
Intravenous |
Aging, limited-market product |
| Zolinza |
Vorinostat |
CTCL |
Oral |
Convenience advantage, older product |
| Beleodaq |
Belinostat |
Relapsed or refractory PTCL |
Intravenous |
Similar rare-disease limitations |
| Tazverik |
Tazemetostat |
EZH2-mutated follicular lymphoma and epithelioid sarcoma |
Oral |
Biomarker and indication-specific differentiation |
| Poteligeo |
Mogamulizumab |
CTCL and adult T-cell leukemia/lymphoma |
Intravenous |
Targeted antibody with distinct mechanism |
| Adcetris |
Brentuximab vedotin |
CD30-positive lymphomas |
Intravenous |
Broader and stronger targeted-oncology franchise |
Romidepsin’s principal disadvantages are its older patent position, infusion burden, and lack of a durable biomarker-defined niche. Its residual value is linked to physician familiarity and treatment options for heavily pretreated patients.
Key Takeaways
- Istodax is romidepsin, an intravenous HDAC inhibitor approved for relapsed or refractory CTCL and PTCL.
- The drug’s commercial opportunity has always been limited by rare-disease prevalence and later-line use.
- Bristol Myers Squibb does not report standalone Istodax revenue, but public disclosures do not indicate blockbuster-scale sales.
- The failed ROMIplus and azacitidine combination programs reduced the probability of label expansion.
- Orphan-drug exclusivity and the principal historical patent protection have expired or reached the end of their commercial life.
- No major active Paragraph IV campaign, patent settlement, or litigation barrier is widely associated with Istodax.
- Generic entry is technically feasible but may be limited by sterile manufacturing costs and the small market.
- The product’s financial trajectory is mature to declining, with little evidence of a credible growth catalyst.
FAQs
Is Istodax still commercially available in the United States?
Public commercial visibility for Istodax has declined substantially, and Bristol Myers Squibb has not provided a recent standalone sales profile. Availability can depend on manufacturer supply and healthcare-channel status.
Is romidepsin a biologic drug?
No. Romidepsin is a small-molecule natural-product derivative. Biosimilar substitution rules do not apply.
Can a generic company obtain FDA approval for romidepsin?
Yes, in principle. A generic applicant would need to satisfy FDA requirements for the injectable product and address any remaining listed patents or regulatory exclusivity.
Why did romidepsin fail to become a frontline lymphoma product?
The major frontline expansion strategy did not demonstrate sufficient clinical benefit in randomized testing. The failure limited the drug to a narrower relapsed or refractory market.
Does Istodax have a strong investment case?
The product alone has a weak growth profile. Its value is more consistent with residual specialty revenue or an opportunistic asset acquisition than with a high-growth oncology franchise.
References
- U.S. Food and Drug Administration. (2009). FDA approves Istodax for cutaneous T-cell lymphoma.
- U.S. Food and Drug Administration. (2011). FDA approves Istodax for peripheral T-cell lymphoma.
- Bristol Myers Squibb. (2020-2024). Form 10-K annual reports.
- Bachy, E., et al. (2022). Romidepsin plus CHOP versus CHOP in previously untreated peripheral T-cell lymphoma. Journal of Clinical Oncology.
- Bristol Myers Squibb. (2021). Bristol Myers Squibb updates clinical development plans for romidepsin-based combinations.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
